Loading cancer entity…
Loading cancer entity…
Clinical trials
806 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05113355 | Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm | unknown | Phase 2 | 23 | Peking Union Medical College HospitalOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT05076786 | Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma | unknown | Phase 2 | 28 | Peking Union Medical College HospitalOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT04284605 | Effects Exercise Training in Patients With Pituitary Adenoma | completed | N/A | 10 | Hacettepe UniversityOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT05061784 | Routine Transcervical Thymectomy in MEN-1 Patients | completed | — | 7 | National University Health System, SingaporeOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT01869725 | Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT | completed | Phase 2 | 68 | Sue O'DorisioOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT04427787 | A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET(LOLA) | unknown | Phase 2 | 69 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT04085081 | Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Aug 12, 2021 | clinicaltrials |
| NCT01465659 | Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 29 | Northwestern UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT01524783 | Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)(RADIANT-4) | completed | Phase 3 | 302 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 5, 2021 | clinicaltrials |
| NCT02948946 | Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors | completed | — | 105 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT02838342 | Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors(EPICentro) | completed | Phase 2 | 28 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT01619865 | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors(GA-68) | completed | Phase 1 / Phase 2 | 223 | Sue O'DorisioOTHER | 1 | Jul 27, 2021 | clinicaltrials |
| NCT04951557 | Setting Benchmarks for Transsphenoidal Resection of Pituitary Adenomas | unknown | — | 5,000 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT03190213 | Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma(Pembro NEC) | terminated | Phase 2 | 6 | University of UtahOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT03189953 | 68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH(GLP-1-AHH) | completed | Phase 1 / Phase 2 | 56 | Radboud University Medical CenterOTHER | 0 | Jun 16, 2021 | clinicaltrials |
| NCT03947762 | Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.(PanNET) | terminated | — | 54 | IpsenINDUSTRY | 2 | Jun 14, 2021 | clinicaltrials |
| NCT03670030 | A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System | terminated | Phase 2 | 5 | Robert RamirezOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT03923257 | Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents | withdrawn | Phase 1 / Phase 2 | 0 | Sue O'DorisioOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT02823691 | The MetNET-2 Trial(MetNET-2) | unknown | Early Phase 1 | 20 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT04073017 | Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency | terminated | N/A | 11 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 21, 2021 | clinicaltrials |
| NCT02810600 | Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors(PET/Ga68) | completed | — | 2,120 | Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT03053284 | Pasireotide in Hyperinsulinemic Hypoglycemia | withdrawn | Phase 2 | 0 | Montefiore Medical CenterOTHER | 0 | May 14, 2021 | clinicaltrials |
| NCT04331912 | PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment | unknown | — | 100 | University of Warmia and MazuryOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04840771 | Predictive OCTA Biomarkers After Endoscopic Endonasal Pituitary Surgery | completed | — | 8 | Federico II UniversityOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT02973204 | Circulating Tumor Cells and Tumor DNA in HCC and NET | completed | — | 167 | University of AarhusOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04863456 | Efficiency and Safety of Different Treatment Strategies in Adults With Pituitary Adenomas With Hypothalamic Involvement | unknown | N/A | 90 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 28, 2021 | clinicaltrials |
| NCT04790708 | Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)(FENET-2016) | unknown | N/A | 250 | University Hospital of FerraraOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT02939651 | A Study of Pembrolizumab in Patients With Neuroendocrine Tumors | completed | Phase 2 | 21 | Fox Chase Cancer CenterOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT04780737 | Prophylactic Cholecystectomy is Not Mandatory in Patients Candidate to the Resection for Small Intestine Neuroendocrine Neoplasms: a Propensity Score-matched and Cost-minimization Analysis | completed | — | 230 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT04390802 | A Pilot Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Pituitary Adenomas | unknown | — | 40 | Massachusetts General HospitalOTHER | 0 | Feb 24, 2021 | clinicaltrials |
| NCT01327612 | Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | completed | Phase 2 | 12 | AmgenINDUSTRY | 3 | Feb 21, 2021 | clinicaltrials |
| NCT04753229 | Ki67 Proliferation Index of Pancreatic Neuroendocrine Neoplasia(TNE-P-Ki) | completed | — | 50 | Institut Paoli-CalmettesOTHER | 0 | Feb 18, 2021 | clinicaltrials |
| NCT03001349 | 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors | terminated | Early Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 15, 2021 | clinicaltrials |
| NCT04546386 | Long-term Follow up for Retinal Vascular Changes After Endoscopic Endonasal Pituitary Surgery. | completed | — | 14 | Federico II UniversityOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04017104 | Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging | unknown | — | 60 | British Columbia Cancer AgencyOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT04207762 | 18F-AmBF3-TATE PET/CT for Imaging NET Patients | completed | — | 10 | British Columbia Cancer AgencyOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04034745 | Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain | withdrawn | — | 0 | Andrew Hendifar, MDOTHER | 0 | Dec 30, 2020 | clinicaltrials |
| NCT00446082 | Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease | completed | Phase 1 | 85 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 21, 2020 | clinicaltrials |
| NCT01263353 | Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs(COOPERATE-1) | completed | Phase 1 | 36 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01364415 | Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) | completed | Phase 1 | 29 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT02441062 | Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors | completed | Phase 2 | 122 | Sue O'DorisioOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04085211 | Image-Enhanced Endoscopy in the Gastrointestinal Tract | unknown | — | 260 | King's College Hospital NHS TrustOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT04622631 | Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT | unknown | — | 80 | Dr. Nayruz KnaanaOTHER_GOV | 1 | Nov 10, 2020 | clinicaltrials |
| NCT04621565 | Hydrocortisone Use During Peri-operation for Pituitary Adenomas | unknown | N/A | 436 | Peking Union Medical College HospitalOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT00326469 | Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours | completed | Phase 2 | 30 | IpsenINDUSTRY | 1 | Nov 5, 2020 | clinicaltrials |
| NCT02853422 | Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours(QUALINETS) | completed | — | 199 | IpsenINDUSTRY | 2 | Nov 5, 2020 | clinicaltrials |
| NCT04491851 | Impact of Peptides and Chelators on Somatostatin Receptor Antagonists | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT04194125 | Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer | unknown | Phase 2 | 25 | University of Warmia and MazuryOTHER | 1 | Nov 4, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Nov 24, 2021source: clinicaltrials